$PLRX News

Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Pliant Therapeutics Announces Dosing Of First Participant In FORTIFY Phase 1b Open-Label Indication Expansion Clinical Trial Of PLN-101095 In Combination With Pembrolizumab, In Patients With ICI-Refractory Advanced Or Metastatic Solid Tumors

Pliant Therapeutics, Inc. (PLRX) Presents at AACR Annual Meeting 2026 - Slideshow

Reported Earlier, Pliant Therapeutics Announced The Updated Data From Its Phase 1 Trial Of PLN-101095, In Combination With Pembrolizumab, In Patients With Immune Checkpoint Inhibitor (ICI)-refractory Advanced Or Metastatic Solid Tumors

Reported Earlier, Pliant Therapeutics Announced The Updated Data From Its Phase 1 Trial Of PLN-101095, In Combination With Pembrolizumab, In Patients With Immune Checkpoint Inhibitor (ICI)-refractory Advanced Or Metastatic Solid Tumors

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Pliant Therapeutics Files Prospectus To Offer Securities Up To $300M

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026

Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3

Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Pliant Therapeutics Q4 EPS $(0.38) Beats $(0.41) Estimate

Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference

Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Pliant Therapeutics, Inc. (PLRX) Presents at Piper Sandler 37th Annual Healthcare Conference - Slideshow